Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents.

Trial Profile

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 29 Sep 2016 Status changed from recruiting to discontinued due to lack of eligible participants to enrol.
    • 06 Jun 2016 Status changed from suspended to recruiting.
    • 17 Nov 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top